People

In order to successfully develop innovative drugs fulfilling unmet medical needs, Oncorena depends on having the right people in the right roles at the right time.

Oncorena is managed as a virtual development company. All the activities in the company are coordinated by a CEO engaging contract research organizations and appropriate consultants. This includes well established consultants and research organizations covering, for example, preclinical testing, safety studies, regulatory questions, clinical manufacturing and control, intellectual property, communication and clinical studies.

Board

Bengt-Åke Bengtsson (Chairman)

Professor of Endocrinology, Sahlgrenska Academy, University of Gothenburg, Sweden, and previous Head of Department of Internal Medicine Sahlgrenska University Hospital. Co-founder of biotech company Tercica CA, US. Board member of AcuCort AB and former board member of DuoCort Pharma AB. PULS Partner.

Börje Haraldsson

Professor, MD, PhD. Senior Global Program Head at Novartis, Basel, Switzerland since 2015. Professorship in Nephrology, Chair and senior Consultant at the University of Gothenburg and Sahlgrenska University Hospital, Sweden (2001-2015). Professor of Physiology (unpaid, since 2016) at the University of Gothenburg. Author of 150+ publications, world class clinical and research expertise, funded by the Swedish Research Council for 25 consecutive years with four years experience of leading global drug development in immunology.

Lena Mårtensson

PhD, Associate Professor in Physiology, Lund University, Sweden. Head Pipeline Sourcing Senior Director, LEO Pharma A/S. Former Director Strategic Planning and Business Development at AstraZeneca, several senior leadership positions at Pharmacia, Medical Director at Perstorp Pharma and Head of Preclinical R&D at Gambro. Board of Director of Genovis. PULS Partner.

Jenny Nyström

Professor in Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden. Expert in renal physiology and molecular mechanisms behind chronic kidney disease, instrumental in preclinical research and development.

Björn Odlander

MD, PhD from Karolinska Institutet, Sweden. Co-founder of HealthCap where he is managing partner since the start in 1996. Before that leading ABB Aros Securities Health Care Equity Research Team. He has extensive experience from multiple boards in the life-science sector including Q-Med AB, NicOx SA, Jerini AG, Nordic Nanovector ASA and BoneSupport AB.

She has wide experience in building new companies. She is CEO of GU Ventures and chair of GOKAP. She has also experience from multiple boards in the life-science sector, including Alzinova, Cellink, Cereno, Metabogen, OnDosis, Ortoma, PExA and Toleranzia.

Innovators

Professor Börje Haraldsson

Professor, MD, PhD. Senior Global Program Head at Novartis, Basel, Switzerland since 2015. Professorship in Nephrology, Chair and senior Consultant at the University of Gothenburg and Sahlgrenska University Hospital, Sweden (2001-2015). Professor of Physiology (unpaid, since 2016) at the University of Gothenburg. Author of 150+ publications, world class clinical and research expertise, funded by the Swedish Research Council for 25 consecutive years with four years experience of leading global drug development in immunology.

Professor Jenny Nyström

Professor in Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden. Expert in renal physiology and molecular mechanisms behind chronic kidney disease, instrumental in preclinical research and development.

Dr Lisa Buvall

Expert in cellular signalling and kidney biology at University of Gothenburg, Sweden. Responsible for preclinical research and development.

Associate Professor Ulf Nilsson

Chemist with comprehensive experience of in vitro and in vivo studies, and from numerous animal models. Long experience serving on the Regional Ethical Review Board for research involving humans. Current position: Senior Advisor at the Research & Innovation Office, University of Gothenburg, Sweden.

MD. Bernard Escudier was chairman of the Gentiourinary tumor board at Gustave Roussy, Villejuif, 2010-2015 and has led multiple phase I to phase III trials as principal investigator. He is interested in renal cell carcinoma, immunotherapy and development of new therapeutic strategies.
He was leading the generation of the ESMO guidelines for kidney cancer in 2012, 2014 and 2016.

Dr Petri Bono, Helsinki University Hospital, Helsinki, Finland

MD, PhD. Chief Medical Officer, Helsinki University Hospital, Helsinki, Finland.
Petri Bono is specialized in targeted treatment of breast and renal cancer and is a member of ESMO and ASCO. Former appointment at Massachusetts Institute of Technology (MIT), US, and fellow at the Helsinki University Hospital.